Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs BAFIERTAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
120 mg orally once daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
30–40% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Not established in pediatric patients.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No specific dose adjustment; use with caution due to age-related decline in renal function.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
No black box warning.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs BAFIERTAM, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and BAFIERTAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and BAFIERTAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.